Clinical Core
Leader: Kaycee Sink, MD, MAS, FACP
Co-Leader: Suzanne Craft, PhD
Overarching Aim of the Clinical Core

• Increase knowledge about the role of metabolic and vascular risk factors in promoting the transition from normal aging to MCI, and then to AD or other forms of pathological brain aging such as vascular cognitive impairment (VCI).

• Our Charge:
  • Establish a well characterized cohort of participants
  • Be a resource to you!
    • We want to share our data
    • Participants are able to be in other studies
Clinical Core Specific Aims

1: To enroll and intensively characterize a cohort of participants with and without prediabetes who are cognitively normal, have MCI, or have Alzheimer’s or mixed dementia

2: To provide resources to address the question of whether participants with prediabetes show greater change over time on measures of cognition and AD pathology, and to explore relationships among novel AD and metabolic biomarkers and symptoms of AD, VCI, and other disorders.

3: To maximize the participation of African American adults and others from diverse racial and ethnic backgrounds, who have higher rates of metabolic and vascular disease, and dementia.

4: To coordinate systematic collection and archiving of brain, biospecimen, genetic, cognitive, metabolic, and imaging data to share with national and local investigators

5: To develop and collect innovative indices of metabolic and vascular risk
Clinical Core Composition
500 participants, ≥55 years old

Normal
- Normoglycemic
  N=75; low risk
- Pre-Diabetic
  N=125; high risk

MCI
- Normoglycemic
  N= ~125
- Pre-Diabetic
  N= ~125

AD/mixed VCI
- N= 50
  Diabetes excluded
Assessments

• Uniform Data Set-3
  • Interview and Physical exam
  • Cognitive assessments: 1.5 hour battery of tests
  • Medications and comorbid conditions
  • Family history
  • Informant reported measures of function, behaviors

• Labs (CMP, CBC, TSH, B12, HA1c, insulin, lipids; Apo-E genotype; CSF a-β, t-tau, p-tau)

• OGGT, DXA, Arterial stiffness

• Neuroimaging
  • MRI on all
  • Amyloid PET & dual AcAc/FDG PET in subset; possibly Tau PET

• Blood, DNA, and CSF stored
# Assessment Schedule

<table>
<thead>
<tr>
<th>Key assessments</th>
<th>Y1</th>
<th>Y2</th>
<th>Y3</th>
<th>Y4</th>
<th>Y5</th>
</tr>
</thead>
<tbody>
<tr>
<td>UDS</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>MRI</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>DXA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>OGTT</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PWV</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bio-intensive Group</th>
<th>Y1</th>
<th>Y2</th>
<th>Y3</th>
<th>Y4</th>
<th>Y5</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>PiB PET</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
<tr>
<td>Dual tracer PET¹</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
<td>S</td>
</tr>
</tbody>
</table>

| Phone assessment²   |    | X  | X  |    | X  |

NL=cognitively normal (metabolically normal and pre-diabetic); X= collected at the visit; S= Bio-intensive group (BIG) substudy participants only; Goal enrollment is 50% CSF, 20% PiB; 15% dual tracer; 1. Dual tracer PET= FDG + Acetoacetate PET; 2. Telephone Assessment: screen positive participants will be brought in for a complete UDS clinical and cognitive assessment and if determined to have clinically significant decline will follow annual assessments on same schedule as MCI participants.
We hope you’ll find ways to use the resources we are building